Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in
combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12
weeks administration and to evaluate the safety and efficacy of MP-513 in combination with
thiazolidinedione with an extension treatment for up to 52 weeks.